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A B S T R A C T   
Introduction: Chronic liver disease (CLD) is characterized by changes in haemostasis, embracing both hypo- and 
hypercoagulability. Global hemostatic tests such as thrombin generation assays evaluate the hemostatic balance, 
to better assess bleeding and thrombotic risks. In addition, procoagulant state in patients with CLD has been 
demonstrated using modified thrombin generation assays with thrombomodulin, a cofactor for protein C acti-
vation. In this study, we prospectively determined thrombin generation and thrombomodulin resistance in pa-
tients with CLD staged with liver stiffness measurement (LSM), using both the fully automated analyzer ST 
Genesia® Thrombin Generation System (STG) and the calibrated automated thrombogram assay (CAT). 
Materials and methods: Demographic, clinical and laboratory characteristics, and blood samples were collected 
from 65 patients with CLD. Liver stiffness was measured by transient elastography, and thrombin generation and 
thrombomodulin resistance, by STG and CAT. 
Results: Patients were separated based on LSM of <21 and ≥21 kilopascals (kPa). The propagation rate of 
thrombin generation was higher in patients with LSM ≥21 kPa and the thrombin generation rate increased as 
LSM increased. In addition, thrombomodulin resistance assessed by STG and CAT was higher in patients with 
LSM ≥21 kPa. However, ETP inhibition by activated protein C was comparable in patients with LSM <21 and 
≥21 kPa. Finally, LSM correlated with most thrombin generation parameters. 
Conclusion: The STG automated system may have value in the assessment of patients with chronic liver disease in 
the routine coagulation laboratory. LSM ≥21 kPa identify a procoagulant phenotype in these patients, including 
thrombomodulin resistance.   
1. Introduction 
Chronic liver disease (CLD) is defined as a progressive destruction of 
the liver parenchyma over a period greater than 6 months leading to 
fibrosis and cirrhosis. This condition affects both pro- and anticoagulant 
forces of the hemostatic system [1]. Therefore, the hemostatic balance in 
CLD is in a fragile equilibrium and may easily shift toward an increased 
or decreased thrombin generation (TG) that eventually may result in 
life-threatening bleeding or thrombotic complications [2–4]. CLD has 
been associated to an increased incidence of thromboembolism [5–7] 
and portal vein thrombosis occurs more frequently in patients with CLD 
[8–10]. Moreover, coagulation factors have been reported to promote 
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fibrosis progression. Several mechanisms have been proposed such as 
thrombin-mediated activation of stellate cells via protease activated- 
receptor-1, as well as tissue ischemia and parenchymal extinction, 
reviewed by Anstee et al. [11]. 
Consequently, anticoagulation might be considered for both fibrosis 
and thrombosis prevention in patients with CLD. Notably, anti-
coagulation with the low molecular weight heparin enoxaparin reduces 
the intrahepatic vascular resistance and improves portal pressure in a 
murine model of cirrhosis [12] and has been shown to delay the 
occurrence of decompensation and to improve survival in patients with 
CLD [13]. 
Coagulation alterations in patients with CLD comprise a concomitant 
decrease of pro-and anticoagulant proteins, except for factor VIII, which 
is increased. Therefore, the hypercoagulability of plasma in these pa-
tients results mainly from increased factor VIII and decreased protein C 
levels [3]. The elevated factor VIII/protein C ratio appears to be 
responsible for the resistance to the anticoagulant effect of thrombo-
modulin (TM), an endothelial receptor playing a key role in the inhibi-
tory process of TG [1,14]. Using a modified TG assay that adds soluble 
TM, it has been shown that the coagulation potential observed in pa-
tients with liver disease is preserved indicating that the deficiency of 
anticoagulant proteins compensates for the deficiency of procoagulant 
proteins [15]. Even in CLD patients with prolonged coagulation times, 
TM-modified TG is normal or even increased compared to healthy in-
dividuals [16,17].Global hemostatic tests such as TG assays provide 
currently the most accurate representation of the coagulation phenotype 
at the individual level [18] and have been used for investigating coa-
gulopathy in CLD in several studies due to their ability to taking into 
account the protein C pathway [9,15,19–23]. Using this methodologic 
approach, La Mura et al. have shown that TM resistance is associated 
with portal vein thrombosis and might predict an adverse outcome in 
patients with CLD [24]. 
Measurement of liver stiffness by transient elastography is a reliable 
method to detect and stage liver fibrosis, and to stratify the prognosis. A 
recent meta-analysis demonstrated for diagnosis clinically significant 
portal hypertension (CSPH) in patients with CLD, that the most sensitive 
validated cut-off is 13 kPa and the most specific cut-off is 21 kPa 
[25–27]. Recently, Dillon et al. reported that liver stiffness measure-
ments (LSM) identify differences in parameters of TG measured by the 
calibrated automated thrombogram (CAT) assay in patients with 
cirrhosis before changes in coagulation times occur [22]. 
In the present study, both the new fully automated analyzer ST 
Genesia® Thrombin Generation System (STG) and the CAT assay were 
evaluated in a cohort of patients with CLD. The aim was to prospectively 
determine TG and resistance to TM in CLD patients staged with LSM, 
using both STG and CAT. 
2. Methods 
2.1. Study design 
Patients affected by CLD were recruited prospectively at a single 
center over a 2-year period (2017–2019). 
Patients presenting with CLD of different etiologies and all stage of 
liver cirrhosis with or without a previous history of clinical decompen-
sation (esophagogastric variceal bleeding, ascites, hepatic encephalop-
athy, spontaneous bacterial peritonitis or hepatorenal syndrome) were 
eligible for this study. Inclusion criteria were: CLD defined as a pro-
gressive destruction of the liver parenchyma over a period greater than 
6 months leading to fibrosis and cirrhosis, age 18–79 years. Exclusion 
criteria were: age <18 and ≥80 years [28], malignancy, ongoing anti-
coagulation therapy, previous history of venous thromboembolism, 
active bacterial/parasitic infection, liver cyst, pancreatitis, inherited 
bleeding disorder, orthotopic liver transplantation, Rendu-Osler-Weber 
disease. The ethic committee at our institution approved the study 
(general consent: 01.02.2016 and retrospective/prospective study 2018- 
00487: 28.03.2018), and written informed consent was obtained from 
all participants. The study protocol conforms to the ethical guidelines of 
the 1975 Declaration of Helsinki as reflected in a priori approval by the 
institution's human research committee. 
2.2. Clinical data collection 
For all enrolled patients, baseline demographic information (age and 
sex, etiology of the CLD, body mass index (BMI), LSM, spleen size, his-
tory of previous decompensation, smoking status, alcohol use, history of 
diabetes, hematocrit and hemoglobin levels, white blood cell and 
platelet counts, prothrombin time (PT), international normalized ratio 
(INR), creatinine, serum albumin, total bilirubin and liver function tests 
such as aspartate transaminase (AST), alanine transaminase and alkaline 
phosphatase (ALP)) were collected. 
2.3. Transient elastographic analysis 
LSM was performed using transient elastography (Fibroscan 502; 
Echosens, Paris, France) as previously reported [29]. Briefly, patients in 
a fasted state were lying in the dorsal decubitus position with the right 
arm in maximal abduction. LSM were realized on the right lobe of the 
liver through intercostal spaces. Using the appropriate probe according 
to the skin-to-capsule distance (M probe or XL probe), an experienced 
operator located a liver portion of at least 6-cm thick and free of large 
vascular structures. At least 10 successful measurements were per-
formed on each patient. Success rate was calculated as the ratio of the 
number of successful measurements over the total number of acquisi-
tions. Only LSM with a success rate of at least 60% and an interquartile 
range/median value below 30% were considered reliable. LSM were 
expressed in kPa and median value was used as representative of LSM. 
2.4. Blood collection and processing 
Venous blood was obtained through antecubital venipuncture and 
collected into 3.2% sodium citrate (2 × 4.3 mL, S-Monovette, Sarstedt, 
Nümbrecht, Germany). Samples were then processed by double centri-
fugation according to the recommendation of the subcommittee of the 
Scientific and Standardization Committee of the ISTH [28,30]. Briefly, 
whole blood samples (2 × 4.3 mL) were centrifuged at 2500g for 15 min 
at room temperature and 3 mL of platelet-poor plasma (PPP) was 
collected in the middle of the tube, thus avoiding the platelets at the top 
surface and those at the buffy coat. The collected plasma was recentri-
fuged at 2500g for 15 min at room temperature and 2.6 mL of super-
natant (platelet-free plasma, PFP) was collected. The resulting PFP was 
stored in aliquots at − 80 ◦C. Measurements were all completed within 2 
months after blood collection. 
2.5. TG assays 
TG measurements were performed with the STG assay (Stago, 
Asnières-sur-Seine, France) and with the CAT assay (Stago, Asnières-sur- 
Seine, France). 
For the STG assay, two types of reagents were used: the STG- 
BleedScreen (STG-BLS) and the STG-ThromboScreen (STG-TS). TG 
with the STG-BLS assay was triggered by a mixture of procoagulant 
phospholipids and low picomolar level of human tissue factor (TF), 
balanced for sensitivity to procoagulant factor deficiencies while mini-
mizing contact activation. The assay contained two quality controls for 
low and normal TG potential, respectively, and a reference plasma for 
parameters normalization. In the STG-TS assay, TG was initiated by a 
mixture of procoagulant phospholipids and medium picomolar level of 
human TF in the presence or absence of TM, balanced for sensitivity to 
deficiencies in natural anticoagulants, without interfering contact acti-
vation. The assay contained three quality controls for low, normal and 
high TM resistance and a reference plasma for parameter normalization. 
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In the presence of both reagents, TG was triggered by dispensing a flu-
orogenic substrate and CaCl2. The following parameters were measured: 
lag time, peak height, time to peak, endogenous thrombin potential 
(ETP), ETP inhibition, and velocity index. Lag time measures the time 
from test initiation until thrombin is detected (min), peak is the highest 
amount of thrombin generated (nM) and time to peak measures the time 
from test initiation until peak (min). ETP represents the area under the 
curve (nM.min). Velocity index is the curve slope until peak (nM/min); 
it represents the rate of thrombin propagation. The ETP inhibition 
evaluates the ETP reduction in presence of TM. For the data analysis, 
only the normalized values of each TG parameters were taken into ac-
count. Data normalization was performed in each assay in relation to an 
internal reference control plasma (STG-Reference Plasma, Stago). 
Normal reference ranges, expressed as interquartile range (25th–75th 
percentile), were recalculated based on data recently published [28] 
excluding donors under oral contraceptive and hormonal replacement 
therapy (n = 110). 
For the CAT assay, two experimental settings were used. 
In the first setting (referred later on as CATlow TF), 74 μL PFP was 
added to 20 μL of a mixture of 1 pmol/L TF and 4 μmol/L phospholipids 
(PPP reagent LOW, Stago), and of recombinant human TM (Sekisui, 
Alveo AG, Switzerland) or 6 μL of HN-buffer (Hepes 20 mM, NaCl 140 
mM, pH 7.4 + 5 mg/mL BSA), in a 96-well round bottom microtiter plate 
(Immulon2HB, Thermo Fischer Scientific, Reinach, Switzerland). The 
concentration of TM of 2 nM was tested in a preliminary assay and 
selected by the ability to decrease by 50% the peak of thrombin. 
For the second setting (referred later on as CAThigh TF), 74 μL PFP was 
added to 20 μL of a mixture of TF and phospholipids (7:3 mixture PPP 
reagent HIGH and MP reagent, Stago, Asnières-sur-Seine, France) and 6 
μL of recombinant human activated protein C (APC) (Enzyme Research, 
Swansea, United Kingdom) or HN-buffer, in a 96-well round bottom 
microtiter plate. The concentration of APC of 16 nM was tested in a 
preliminary assay and selected by the ability to decrease by 90% the ETP 
[31]. 
The reaction was initiated with 20 μL of a mixture of fluorogenic 
substrate and CaCl2 (Fluobuffer, Stago, Asnières-sur-Seine, France) and 
fluorescence measured using a fluorescence plate reader (Fluoroskan 
Ascent, Thermo Labsystems, Helsinki, Finland). All experiments were 
carried out in duplicate at 37 ◦C for each assay. In addition, the same 
normal control plasma (Cryocheck Reference Control Normal, Pre-
cisionBiologic, Dartmouth, Canada) was tested in all experiments in 
order to correct day-to-day variations. TG curves were generated using 
the Thrombinoscope software version 5.0.0.742 (Thrombinoscope BV, 
Maastricht, The Netherlands). Lag time, peak height, time to peak, ETP 
and the ETP ratio obtained in presence/absence of TM or APC was 
calculated. Results from the control plasma were used to calculate the 
normalized ETP ratio as follow [32,33]: (Patient ETP+TM/Patient ETP- 
TM)/(Control ETP+TM/Control ETP-TM) and (Patient ETP+APC/Patient 
ETP-APC)/(Control ETP+APC/Control ETP-APC). 
Based on the measurement on 111 normal plasma samples, we 
determined that normalized ETP ratio in presence/absence of TM above 
1 and normalized ETP ratio in presence/absence APC above 2 are 
normal. 
2.6. Statistical analysis 
Continuous variables were expressed as median and interquartile 
range (25th–75th percentile) or as mean and standard deviation (SD). 
Groups were compared by using the Mann–Whitney U test for inde-
pendent samples and Tukey's multiple comparisons test. The Spearman 
correlation was calculated to verify the association between different 
parameters. Contingency tables were analyzed by Fisher's test. Statisti-
cal analysis was performed using Graphpad Prism 7 software (GraphPad 
Software, San Diego, CA, USA). 
3. Results 
3.1. Characteristics of the patients cohort 
Of 141 screened patients with CLD, we excluded 70 at the time of the 
TG analyses because of ineligibility and 6 after enrollment due to no 
LSM, leaving a study sample of 65 patients (Fig. 1). Due to volume 
limitation of the plasma samples, 58 samples were assessed by CAT, 50 
samples by STG and 43 by both STG and CAT (Fig. 1). Characteristics at 
Fig. 1. Flow diagram of patients included in the study. CLD, advanced chronic liver disease.  
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the time of the TG analyses are shown in Table 1. 
Overall, 39 patients (60%) were men with a median age of 58 years 
(interquartile range [IQR] 48–67 years). CLD etiology was identified in 
92% of patients. Disease severity was staged based on LSM according to 
the EASL-ALEH guidelines [29]. A cut-off of 21 kPa was used to identify 
patients with a high likelihood of bearing clinically significant portal 
hypertension [22,26,34,35]. 
Patients with elevated LSM (≥21 kPa) at the time of the TG mea-
surement were slightly older in the group assessed by CAT than in the 
group assessed by STG (median age of 67 versus 60 years, P < 0.05). 
Patients with elevated LSM had a higher BMI and showed higher prev-
alence of previous decompensation. Only patients with elevated LSM 
belonging to the CAT group had a slightly lower hematocrit and he-
moglobin levels. Patients with elevated LSM had lower platelet counts 
and albumin concentration. They had also more prolonged PT as well as 
higher INR, bilirubin, AST, AST:ALT ratio and ALP. 
3.2. TG parameters and liver stiffness measurements 
Both the lag time to TG and peak TG assessed either by STG or CAT 
were comparable in the group with LSM <21 kPa and in the group with 
LSM ≥21 kPa (Figs. 2-3). 
The time to peak TG was shorter in the group with LSM <21 kPa 
when measured either by STG-TS (medium picomolar TF concentration) 
Table 1 
Demografic, clinical and laboratory characteristics of the studied population according to liver stiffness measurements and thrombin generation analysis. LSM, liver 
stiffness measurement; BMI, body mass index; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase; AIH, autoimmune hepatitis; ALD, alcoholic liver diseases; HBV, hepatitis B virus; HCV, hepatitis C virus; HFE, hereditary hemochromatosis, NAFLD, non- 
alcoholic fatty liver disease; PBC, primary biliary cholangitis.  
Characteristic All ST Genesia P Calibrated automated thrombography P 
<21 kPa ≥21 kPa <21 kPa ≥21 kPa 
n 65 38 12 – 43 15 – 
Sex (% men) 60 50 83 ns 54 80 * 
Age (years) 58 (48–67) 55 (43–64) 60 (56–68) ns 55 (43–64) 67 (57–70) * 
Etiology AIH (n = 6) 
ALD (n = 16) 
HBV (n = 8) 
HFE (n = 4) 
HCV (n = 16) NAFLD (n =
5) 
Unknown (n = 5) 
PBC (n = 4) 
drug-induced (n = 1) 
AIH (n = 5) 
ALD (n = 2) 
HBV (n = 8) 
HFE (n = 2) 
HCV (n = 10) 
NAFLD (n = 4) 
Unknown (n = 3) 
PBC (n = 4) 
ALD (n = 8) 
HCV (n = 2) 
Unknown (n = 1) 
drug-induced (n =
1) 
– AIH (n = 6) ALD(n = 2) 
HBV (n = 8) 
HFE (n = 3) 
HCV (n = 12) NAFLD (n =
3) 
Unknown (n = 4) 
PBC (n = 4) 
ALD (n = 11) 
HCV (n = 2) 







































8 3 33 ** 0 29 ** 
Smoking status (%) 45 42 58 ns 40 47 ns 
Alcohol use (%) 49 48 33 ns 54 47 ns 
Diabetes 
(%) 


























































INR (ratio) 1.03 (1.0–1.1) 1.01 (1.0–1.03) 1.2 (1.05–1.4) *** 1.01 (1–1.03) 1.2 (1.05–1.5) **** 











Albumin (g/L) 38 (34–40) 39 (37–40.3) 29 (27–34) **** 38 (36.5–40) 27 (25–33) **** 























































Groups were compared using the Mann-Whitney U test. Data are expressed by median and interquartile range (25th–75th percentiles). ns, non-significant. 
* P < 0.05. 
** P < 0.01. 
*** P < 0.001. 
**** P < 0.0001. 
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or CAT assay with high TF concentration (LSM <21 kPa: 1.31 ± 0.33; 
LSM ≥21 kPa; 1.08 ± 0.38; mean ± SD; P = 0.0058), but not when 
measured either with STG or CAT in presence of a low TF concentration 
(Fig. 4A-D). The ETP measured either by STG or CAT assay was com-
parable in the group with LSM <21 kPa and in the group with LSM ≥21 
kPa (Supplementary Fig. 1). 
ETP inhibition assessed by STG was higher in the group with LSM 
<21 than in the group with LSM ≥21 kPa (LSM <21 kPa: 57.5 ± 20.7; 
LSM ≥21 kPa; 33.4 ± 24.4, mean ± SD, P = 0.0057; Fig. 5A). Notably, 
ETP inhibition in the LSM group ≥21 kPa was remarkably decreased 
when compared with normal reference interval [28] (gray area in 
Fig. 5A). Similarly, ETP ratio normalized values with or without TM 
measured by CAT were significantly different in the two LSM groups 
(LSM <21 kPa: 1.09 ± 0.50; LSM ≥21 kPa: 2.23 ± 1.52; P = 0.007, 
respectively; Fig. 5B). Since the not normalized ratio is currently used in 
the literature, it is worth noting that the ETP ratio not normalized was 
also increased in the LSM group ≥21 kPa (LSM <21 kPa: 0.33 ± 0.19; 
LSM ≥21 kPa: 0.52 ± 0.29; mean ± SD; P = 0.0196; Supplementary 
Fig. 2A). Importantly, ETP inhibition (measured by STG-TS) negatively 
correlated with the not normalized ETP ratio (measured by CAT) 
(Supplementary Fig. 2B). All together, these data suggest that patients 
with LSM ≥21 kPa displayed a hypercoagulability due to a resistance to 
TM. 
Since reagents and settings are different in STG and CAT, the rela-
tionship between ETP inhibition evaluated by the two systems was 
analyzed. STG-ETP inhibition correlated strongly with CAT-ETP ratio 
normalized (r = − 0.74, p < 0.0001; Fig. 6A). 
Resistance to the anticoagulant activity of TM can result from an 
impaired protein C, protein S, factor V and factor VIII synthesis or ac-
tivity. In order to define the role of protein C in the observed resistance 
to TM, we analyzed TG by CAT in presence or absence of exogenous 
activated PC. Activated protein C-modified TG was comparable in the 
LSM group <21 kPa and the LSM group ≥21 kPa (Fig. 5C). Finally, there 
was no correlation between activated protein C and TM sensitivities 
(assessed by CAT or STG, Fig. 6A-C). 
The velocity index (or rate of propagation), only when measured by 
STG-TS (medium picomolar TF concentration), was higher in the LSM 
group ≥21 kPa than in the LSM group <21 kPa (Fig. 7A-D). 
3.3. Correlation between TG and liver stiffness measurements 
Since the evaluation of the liver stiffness is a reliable method for the 
staging of CLD [29] and is associated with clinically significant portal 
hypertension [36], we calculated the correlation (coefficients) of the 
Fig. 2. Lag time to thrombin generation (TG) 
measured by ST Genesia (STG) and CAT assay in a 
cohort of patients with CLD separated based on liver 
stiffness measurement (LSM). (A) Lag time to TG 
normalized measured by STG-BleedScreen (BLS) 
assay. (B) Lag time to TG normalized measured by 
STG-ThromboScreen (TS) assay (without thrombo-
modulin, TM). (C) Lag time to TG measured by CAT 
assay with low tissue factor (TF) concentration. (D) 
Lag time to TG measured by CAT assay with high TF 
concentration. Median, 25th to 75th percentiles, 
minimal and maximal values are indicated. The re-
gion filled in gray indicates the reference range 
(25th–75th percentiles) in a healthy adult population 
[28]. Groups were compared using the Mann- 
Whitney U test.   
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linear regression model (r) and P values between TG parameters and 
LSM in the study group (Supplemental Table 1). 
In STG-BLS (low picomolar TF concentration), normalized values of 
peak height, ETP and velocity index positively correlated with LSM, 
while normalized values of time to peak negatively correlated with LSM. 
In STG-TS (medium picomolar TF concentration), normalized values of 
peak height and velocity index correlated positively with LSM, while 
normalized values of time to peak and ETP inhibition correlated nega-
tively with LSM. In contrast, ETP did not correlate with LSM. 
When using CAT assay, both peak height and ETP did not correlate 
with LSM. When using CAT assay with low picomolar TF concentration, 
lag time and time to peak correlated negatively with LSM, while 
normalized ETP ratio with or without TM positively correlated with 
LSM. When using CAT assay with high picomolar TF concentration, lag 
time and time to peak correlated negatively with LSM. 
Finally, normalized ETP ratio with or without APC did not correlate 
with LSM. 
4. Discussion 
In this study, we report TG data from the newly automated analyzer 
ST Genesia® (STG) and the CAT assay in a prospective cohort of 
heterogeneous patients affected by CLD and provide a comparison. Since 
the measurement of the liver stiffness is a reliable method for the staging 
of CLD [29,36], LSM was used to stage the patients included in the CLD 
cohort. We used a cut-off of 21 kPa to subgroup the patients' sample, as a 
LSM ≥21 kPa is currently considered the best non-invasive surrogate 
marker of clinically significant portal hypertension [22]. 
STG is the first fully automated TG analyzer that could be suitable for 
the accurate measurement of TG parameters in patients. Reference in-
tervals have been previously determined in a single study involving a 
small population of healthy adults and need further validation [28]. The 
main finding of the current study is that resistance to TM assessed by 
STG and CAT assays was higher in the group of CLD patients with 
clinically significant portal hypertension as identified by LSM ≥21 kPa. 
However, ETP inhibition by APC was comparable in patients with LSM 
of <21 and ≥21 kPa. Consequently, resistance to TM determined in this 
study seems to be related to an impaired protein C synthesis/activity 
more than to an increased factor VIII and/or factor V synthesis/activity, 
in line with a previous report [37]. 
We also observed that the time to peak TG (or the time to reach the 
highest thrombin concentration) measured by STG and CAT in presence 
of high TF was shorter in patients with LSM ≥21 kPa. For the group with 
LSM ≥21 kPa, the time to peak was shorter compared with normal 
Fig. 3. Peak thrombin generation (TG) measured by 
ST Genesia (STG) and CAT assay in a cohort of pa-
tients with CLD separated based on liver stiffness 
measurement (LSM). (A) Peak TG normalized 
measured by STG-BleedScreen (BLS) assay. (B) Peak 
TG normalized measured by STG-ThromboScreen 
(TS) assay (without thrombomodulin, TM). (C) Peak 
TG measured by CAT assay with low TF concentra-
tion. (D) Peak TG measured by CAT assay with high 
TF concentration. Median, 25th to 75th percentiles, 
minimal and maximal values are indicated. The re-
gion filled in gray indicates the reference range 
(25th–75th percentiles) in a healthy adult population 
[28]. Groups were compared using the Mann- 
Whitney U test.   
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Fig. 4. Time to peak thrombin generation (TG) 
measured by ST Genesia (STG) and CAT assay in a 
cohort of patients with CLD separated based on liver 
stiffness measurement (LSM). (A) Time to peak TG 
normalized measured by STG-BleedScreen (BLS) 
assay. (B) Time to Peak TG normalized measured by 
STG-ThromboScreen (TS) assay (without thrombo-
modulin, TM). (C) Time to peak TG measured by CAT 
assay with low TF concentration. (D) Time to peak TG 
measured by CAT assay with high TF concentration. 
Median, 25th to 75th percentiles, minimal and 
maximal values are indicated. The region filled in 
gray indicates the reference range (25th–75th per-
centiles) in a healthy adult population [28]. Groups 
were compared using the Mann-Whitney U test. *P <
0.05, **P < 0.01.   
Fig. 5. Resistance to thrombomodulin (TM) measured by ST Genesia (STG) and CAT assay in a cohort of patients with CLD separated based on liver stiffness 
measurement (LSM). (A) Endogenous thrombin potential (ETP) inhibition measured by STG-ThromboScreen (TS) assay. The region filled in gray indicates the 
reference range (25th–75th percentiles) in a healthy adult population [28]. (B) Normalized ETP ratio with and without TM measured by CAT assay. Values above the 
dot line at 1 are considered normal. (C) Normalized ETP ratio with and without activated protein C (APC) measured by CAT assay was used as a control. Values above 
the dot line at 2 are considered normal. **P < 0.01. 
J. Brodard et al.                                                                                                                                                                                                                                 
Thrombosis Research 207 (2021) 40–49
47
reference ranges [28] as depicted by the gray area in Fig. 4B. 
Liver stiffness shows correlation with both STG and CAT, although 
the STG assay may be better as more of its parameters correlate with 
LSM in the studied cohort. In particular, liver stiffness showed a mod-
erate correlation with the velocity index (or TG rate) measured with 
STG. Moreover, when samples were grouped according to LSM cutoff, 
Fig. 6. Correlations between ETP ratio normalized and ETP inhibition with and without thrombomodulin (TM) and with an without APC assessed by ST Genesia and 
Calibrated automated thrombography in a cohort of patients with CLD (A) Correlation between the ETP ratio normalized with and without TM (measured by CAT 
assay) and the ETP inhibition (measured by STG-TS) in a subgroup of the cohort (n = 43). (B) Correlation between the ETP inhibition (measured by STG-TS) and the 
ETP ratio with and without APC (measured by CAT) in a subgroup of the cohort (n = 22). (C) Correlation between the normalized ETP ratio with and without TM and 
with and without APC measured by CAT assay, in a subgroup of the cohort (n = 29), 25th to 75th percentiles, minimal and maximal values are indicated. 
Fig. 7. Velocity index (or rate of propagation) 
measured by ST Genesia (STG) and CAT assay in a 
cohort of patients with CLD separated based on liver 
stiffness measurement (LSM). (A) Velocity index 
measured by STG-BleedScreen (BLS) assay. (B) Ve-
locity index measured by STG-ThromboScreen (TS) 
assay (without thrombomodulin, TM). (C) Velocity 
index measured by CAT with low TF concentration 
(TF). (D) Velocity index evaluated by CAT with high 
TF concentration. Median, 25th to 75th percentiles, 
minimal and maximal values are indicated. The re-
gion filled in gray indicates the reference ranges 
(25th–75th percentiles) in a healthy adult population 
[28]. Groups were compared using the Mann- 
Whitney U test. *P < 0.05.   
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there was a significant difference in the velocity index measured by STG 
only in presence of high TF. For the group of patients with LSM ≥21 kPa, 
the velocity index was increased compared with normal reference 
ranges [28] as depicted by the gray area in Fig. 7B. However, the 
increased TG rate in the group with LSM ≥21 kPa was not observed in 
CAT data (Fig. 7C-D). This difference between the two instruments could 
be due to differences in reagents composition and to the distinctive al-
gorithms used for the evaluation of TG rate (Stago, Asnières-sur-Seine, 
France, personal communication). Taken together these data suggest 
that the propagation phase of TG is impaired with liver disease wors-
ening (defined by LSM increase). 
Conventional coagulation tests do not reflect the hemostatic balance 
in patients with CLD [1]. In patients with CLD, TG and TM-modified TG 
are currently considered a more accurate measure of the in vivo coag-
ulation, because it can assess both pro- and anticoagulant forces 
[15,19–22,38–40]. There is evidence of a procoagulant imbalance in 
patients with CLD. Similarly to Gatt et al., we found that patients with 
CLD and clinically significant portal hypertension (identified by LSM) 
displayed an increased propagation rate compared to healthy controls 
[19]. In addition, in line with Dillon et al., we were able to show that 
LSM measurements identify differences in TG parameters in patients 
with CLD [22]. However, the study of Dillon et al. focused on patients 
with well-compensated cirrhosis and observed a reduced TG predomi-
nantly in patients with LSM >35 kPa and did not report on TM resis-
tance. Another publication [24] has shown the association between TM 
resistance and de novo portal vein thrombosis as well as low survival in 
patients with cirrhosis. 
Our study has some limitations. First, the study included only 65 
patients with CLD from a single center. Second, only a small number of 
patients with LSM ≥21 kPa (12 analyzed by STG and 15, by CAT) have 
been included in the study. Thus, confirmation on a larger cohort 
comprising a higher number of patients with LSM ≥21 kPa would be 
required, and a multicenter study would certainly be the most appro-
priate design. Third, the absence of follow-up of the patients precluded 
an assessment of bleeding and thrombotic events. Fourth, due to volume 
limitation of the plasma samples, not all of the samples were assessed by 
both STG and CAT. Fifth, about 10 patients LSM <21 kPa displayed a 
resistance to TM, indicating that a possible procoagulant state has been 
detected at an early stage of the disease. A prolonged follow-up of these 
patients would have been necessary to figure out the impact of this 
finding. Sixth, patients with LSM ≥21 kPa had a higher BMI. This is a 
potential confounding factor because high BMI can increase TG [41]. 
Seventh, we did not measure protein C and S and coagulation factors. All 
these limitations will be taken into account for the design of a larger 
study aiming at confirming our current findings. 
In conclusion, the STG automated system with BleedScreen and 
ThromboScreen assays may be a suitable routine coagulation laboratory 
instrument for the measurement of TG parameters in patients with CLD. 
Since LSM is broadly used to assess CLD progression, its use in combi-
nation with TG changes and the development of a TM resistance may 
constitute a new approach for the follow up of CLD patients that has to 
be investigated in larger, multicenter, cohort studies. In particular, these 
future studies will be necessary to determine whether resistance to TM 
and LSM in patients with CLD could help to predict decompensation or 
identify patients at higher risk of portal vein thrombosis at an early stage 
on. These findings could give more insight to the treated hepatologist to 
decide whenever an anticoagulation therapy should be started in CLD 
patients. 
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